20.01.2026 13:25 | The Guardian World
US-based biotech firm is developing treatment for allergies such as nuts, milk and eggs in children and adultsBusiness live – latest updatesGSK, the UK’s second-biggest drugmaker, has unveiled a $2.2bn (£1.6bn) deal to acquire a Californian biotech company which owns a drug that aims to protect against severe food allergies such as nuts, milk and eggs.It is the first large deal announced by GSK’s new chief executive Luke Miels, who joined the London-based company in 2017 as chief commercial officer and took the reins from Emma Walmsley at the start of the year. Continue reading...
🔗 Citește articolul complet pe The Guardian World
19.10.2026 00:34 | Prosport
19.10.2026 00:24 | Sport.ro
19.10.2026 00:23 | Mediafax
19.10.2026 00:23 | Ziarul Financiar
19.10.2026 00:22 | The Guardian World
19.10.2026 00:18 | Prosport